Terminé

Myocardial Ultrasonic Tissue Characterization in Patients With a Genetic Predisposition for the Development of Hypertrophic Cardiomyopathy

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Collecte de données

Qui peut participer

Maladie de la valve aortique+10

+ Sténose aortique sous-valvulaire

+ Sténose de la valve aortique

Voir tous les critères d'éligibilité
Comment se déroule l'étude

Observationnel
Date de début : septembre 1997
Voir le détail du protocole

Résumé

Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 septembre 1997

Date à laquelle le premier participant a commencé l'étude.

Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease that is characterized by unexplained left ventricular hypertrophy (LVH) often associated with diastolic dysfunction and myocardial ischemia. In patients with HCM, LVH may be present at birth or it may develop during childhood and adolescence, usually during periods of rapid body growth. Currently, it is not possible to identify, using clinical or laboratory methods, those children who will develop LVH from among those with a genetic predisposition for the disease. It would therefore be beneficial to find predictors of LVH development in normal children who have family history of HCM. Integrated backscatter analysis (IBS) is a recently developed ultrasound tool that has been studied in patients with various cardiac diseases. Integrated myocardial backscatter has been shown to vary throughout the cardiac cycle in normal subjects, both pediatric and adult, with peak values occurring during diastole and minimum values in end systole. Several studies in both children and adults with HCM have shown a blunting of this variation in backscatter analysis. We hypothesize that patients with a genetic predisposition for HCM, but no echocardiographic evidence of the disease, may have a greater prevalence of alterations in integrated myocardial backscatter when compared to children without a family history of HCM. We therefore propose to examine the cyclic variation of integrated myocardial backscatter in children with a normal echocardiogram and a first-degree relative with HCM, and compare it with the results obtained in a group of normal children, as well as in a group of children with unequivocal echocardiographic evidence of HCM.

NCT00001632
Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

195 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Maladie de la valve aortiqueSténose aortique sous-valvulaireSténose de la valve aortiqueMaladies CardiovasculairesMaladies CardiaquesCardiomégalieMaladies des Valves CardiaquesCardiomyopathiesConditions pathologiques, signes et symptômesConditions pathologiques anatomiquesCardiomyopathie hypertrophiqueHypertrophieHypertrophie du ventricule gauche

Critères

INCLUSION CRITERIA: Three groups of subjects (aged 1-15 years) will be studied: normal children, children with HCM, and children that are family members of patients with HCM, but do not themselves have any evidence of LVH. CONTROL GROUP (NORM GROUP): Normal children under the age of 15 who have a normal two-dimensional echocardiogram will be included in the study. HYPERTROPHIC CARDIOMYOPATHY GROUP (HCM GROUP): Patients with HCM (unexplained LVH on two-dimensional echocardiogram) under the age of 15 will be included. Family History of Hypertrophic Cardiomyopathy Group (FHCM GROUP: Normal children under the age of 15 who have a first-degree relative with HCM and a normal two-dimensional echocardiogram will be included. EXCLUSION CRITERIA - CONTROL GROUP: Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or any form of cardiomyopathy. EXCLUSION CRITERIA - HCM GROUP: Exclusion criteria will be any evidence of congenital or valvular heart disease that may explain the presence of LVH. EXCLUSION CRITERIA - FHCM GROUP: Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or other form of cardiomyopathy.

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

National Heart, Lung and Blood Institute (NHLBI)

Bethesda, United StatesOuvrir National Heart, Lung and Blood Institute (NHLBI) dans Google Maps
Terminé1 Centres d'Étude